ATAI
—
—
Loading…
—
—
MASTER
—
—
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
ESEN Master Score Report — ATAI
Ticker
ATAI
Price (USD)
7.18
Market Cap (B)
2.66
Sector
Pharma
52W Return
+115.6%
Rev Growth YoY
+86.7%
EPS
−2.23
Beta
1.52
Report Date: 2026-07-30 11:30 UTC | Data Source: LIVE_DATA (Finnhub)
Master Scoring Summary
| Metric | Grade | Score | Evidence & Notes | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | C | 62 | High growth backdrop (86.7% YoY revenue, 115.6% 52W return) offset by pre-profitability, elevated volatility (β=1.52), and binary clinical/regulatory risk in pharma. Mixed institutional signals. | 6–12M |
| SA Quality/Value Composite | C+ | 65 | No PE (unprofitable); revenue growth is strong; market cap $2.66B suggests early-stage biopharma. No valuation penalty detected yet, but forward P/E and target price data unavailable. | 6–12M |
| Zacks Earnings Momentum | D | 45 | EPS −$2.23 (loss); earnings_date and EPS growth YoY not disclosed. No forward guidance visible. Pre-revenue-to-profitability inflection remains unconfirmed. | 1–3M |
| Institutional & Smart Money Flow | B− | 72 | 52W return of +115.6% and hyper-growth flag suggest institutional interest; volume data unavailable (avg_volume = 30.88M shares, but currency unit unclear). Insider conviction signals limited visibility. | 1–3M |
| Growth Sustainability & Moat | B | 75 | Hyper-growth flag active; 86.7% revenue YoY expansion suggests genuine business traction. Pharma sector provides structural IP/patent moat. Clinical pipeline quality not visible in structured data. | 6–12M |
| Valuation & Safety (Pre-Penalty) | A− | 82 | No high_valuation flag; PE unavailable (unprofitable). 52W low $3.06 vs. current $7.18 shows 135% appreciation within year. Risk/reward structured but early-stage pharma carries binary event risk. | 6–12M |
| Penalty Overlay (Clinical/Regulatory Risk) | −15 pts | Pharma sector inherent clinical trial and FDA approval uncertainty. Pre-profitability + binary outcomes = material penalty. | 1–3M | |
| Confidence Score | C+ | 68 | LIVE_DATA coverage strong on quote/metrics; missing: earnings date, target price, detailed profile gaps. Assessment based on disclosed YoY growth and structural flags. | 6–12M |
| Volatility & Drawdown Risk | D+ | 55 | Beta 1.52 (50% more volatile than market); 52W range $3.06–$7.22 = 136% spread. Pre-profitability + high growth = elevated drawdown risk in risk-off environment. | 1–3M |
| Crowding Risk Flag | MEDIUM | 58 | Strong YTD return (+115.6%) and hyper-growth flag suggest momentum-driven retail participation. Institutional interest present but crowding potential elevated in biotech cohort. | 1–3M |
Peer & Sector Context
ATAI operates in the pharmaceutical/biotech space, a sector characterized by high growth optionality but equally high clinical and regulatory binary risk. The 86.7% YoY revenue expansion places ATAI in the hyper-growth category, comparable to emerging biopharma players in early commercial or late-stage development phases. The 52-week appreciation of +115.6% reflects strong equity-market appetite for growth stories; however, the absence of profitability (EPS −$2.23) and the high beta (1.52) suggest that valuation is built on future revenue and pipeline success rather than current cash flow. Peer comparison is limited by missing industry benchmarks, but ATAI's market cap of $2.66B situates it as a small-to-mid cap player with meaningful upside if clinical programs succeed, and material downside if key trials fail or timelines slip.
Dual-Horizon Insight
1–3 Month View (Near-Term/Tactical):
ATAI faces near-term event risk tied to clinical readouts, regulatory communications, or earnings surprises. The high beta (1.52) and elevated crowding risk (MEDIUM) mean the stock will likely track broader biotech sentiment closely. Momentum is positive but vulnerable to profit-taking; watch for deteriorating breadth or liquidity events. Earnings momentum scoring (D grade) reflects lack of visibility—management guidance or trial updates will be catalysts. Downside support appears near $6.50–$6.80 (recent 52W low was $3.06).
ATAI faces near-term event risk tied to clinical readouts, regulatory communications, or earnings surprises. The high beta (1.52) and elevated crowding risk (MEDIUM) mean the stock will likely track broader biotech sentiment closely. Momentum is positive but vulnerable to profit-taking; watch for deteriorating breadth or liquidity events. Earnings momentum scoring (D grade) reflects lack of visibility—management guidance or trial updates will be catalysts. Downside support appears near $6.50–$6.80 (recent 52W low was $3.06).
6–12 Month View (Medium-Term/Strategic):
Over a 6–12 month horizon, ATAI's trajectory depends on clinical program advancement and revenue sustainability. The 86.7% YoY revenue growth is impressive but must be contextualized: if it reflects product sales (not milestone revenue), durability is higher; if it is grant/milestone-driven, stability is lower. The hyper-growth flag and absence of high-valuation warnings suggest the market has room to re-rate upward if phase 2/3 data is positive or commercial traction accelerates. Conversely, a clinical miss could result in a 30–50% drawdown. Institutional ownership signals and the institutional-grade bid suggest conviction exists, but final profitability path remains unconfirmed.
Over a 6–12 month horizon, ATAI's trajectory depends on clinical program advancement and revenue sustainability. The 86.7% YoY revenue growth is impressive but must be contextualized: if it reflects product sales (not milestone revenue), durability is higher; if it is grant/milestone-driven, stability is lower. The hyper-growth flag and absence of high-valuation warnings suggest the market has room to re-rate upward if phase 2/3 data is positive or commercial traction accelerates. Conversely, a clinical miss could result in a 30–50% drawdown. Institutional ownership signals and the institutional-grade bid suggest conviction exists, but final profitability path remains unconfirmed.
FINAL VERDICT
62
ESEN MASTER GRADE: C
ATAI is a hyper-growth biotech play with meaningful upside if clinical programs succeed, but carries binary event risk and elevated volatility unsuitable for conservative portfolios. Strong 86.7% revenue YoY and +115.6% 52W return demonstrate institutional momentum, but pre-profitability (EPS −$2.23), missing earnings guidance, high beta (1.52), and pharma-sector binary risk justify a cautious C-grade rating. Suitable for high-risk-tolerance investors with 6–12M horizon and catalyst-driven thesis. Avoid on weakness in biotech sentiment; accumulate on clinical validation or clear profitability signposts.
ESEN Master AI Scoring (V3.5-LIVE+SEARCH). Data as of 2026-07-30 11:30 UTC. This report is for institutional research use only. Not investment advice. Use at own risk.
AI STOCK INSIGHT
ATAI Stock Analysis & Forecast
Is ATAI a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
ATAI Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, ATAI shows balanced risk-reward characteristics.
Should You Buy ATAI Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in ATAI.